Bringing the circular healthcare economy to life
Neroli Manning is the Managing Director for Cardinal Health Australia & New Zealand (ANZ). With over 30 years of experience in the healthcare industry, Neroli is a transformative leader known for her people-first, customer-centric leadership style.
Op-Ed: CGT and proposed RDTI changes creating uncertainty in life sciences
Proposed Budget changes to the Research and Development Tax Incentive (RDTI) will disproportionally impact Australia’s biotech, medtech and health tech sector forcing more home-grown companies to consider moving overseas.
Using human skin hair follicles to treat Alzheimer’s disease
Professor Michael Valenzuela is a science opinion leader, innovator and creative thinker with a career-long commitment to the prevention and treatment of dementia.
Following that he completed graduate medicine and medical training at the Prince of Wales Hospital. In 2012, he established the Regenerative Neuroscience Group at the University of Sydney, and in 2017 became the university’s first Professor of Regenerative Medicine.
Professor Valenzuela’s group discovered a new cell type with potential for regenerative medicine, a rare neural precursor cell found deep within the human hair follicle. He is the main inventor on several related patents and is the Founder and Chief Scientific Officer of Skin2Neuron – a biotech company developing the first neurorestorative cell therapy for Alzheimer’s disease based on this work.
HEALTH CARE BRIEF: Pelvic Floor Dysfunction
Pelvic Floor Dysfunction – Lived experience, symptoms, diagnosis and treatment options
ICTD: Why negative results in clinical trials matter
To mark International Clinical Trials Day 2026, Australian Health Journal commences a 4 part special series leaving up to 20th May. Through conversations with leading researchers, clinicians and trial organisations, the series highlights achievements in the year that was for clinical trials.
Negative results in a clinical trial can be extremely valuable — both scientifically and ethically. A “negative result” usually means the treatment being tested did not work better than the standard treatment, placebo, or expected outcome.
Negative results in a clinical trial can be extremely valuable — both scientifically and ethically. A “negative result” usually means the treatment being tested did not work better than the standard treatment, placebo, or expected outcome.
Observations in diagnosis and treatment of oral cancer over the past 45 years
Peter Thomson is Academic Head of Dentistry and Professor of Oral & Maxillofacial Sciences in the College of Medicine & Dentistry at James Cook University, Australia. A UK and Australian specialist in Oral & Maxillofacial Surgery and Oral Medicine, he qualified BDS from Manchester University and MBBS from Newcastle upon Tyne, gaining Fellowships in Dental Surgery from the Royal College of Surgeons of England, Ireland and Glasgow and a Fellowship in Surgery from Edinburgh, specializing in Head & Neck Oncology.